Skip to main content
Aptorum Group Ltd logo

Aptorum Group Ltd — Investor Relations & Filings

Ticker · APM ISIN · KYG6096M1069 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2026-06-10 Declaration of Voting R…
Country US United States of America
Listing US APM

About Aptorum Group Ltd

https://www.aptorumgroup.com/

Aptorum Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs. The company's research and development pipeline targets a range of therapeutic areas, including orphan oncology, infectious diseases, and metabolic diseases. Key projects include SACT-1, a repurposed drug candidate for neuroblastoma, and ALS-4, an anti-virulence, non-bactericidal therapeutic for infections caused by Staphylococcus aureus. Additionally, the company is developing its RPIDD (Rapid Pathogen Identification and Detection Diagnostics) platform, a liquid biopsy-based technology for rapidly identifying and detecting pathogens.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer solely to disclose the voting results of an extraordinary general meeting (share consolidation, domestication, merger approval, director appointments, etc.) with detailed vote tallies. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category, which covers official shareholder vote outcome disclosures.
2026-06-10 English
PROSPECTUS
Regulatory Filings Classification · 85% confidence The document is clearly an SEC prospectus filed pursuant to Rule 424(b)(3) in connection with a registration statement (Registration No. 333-291593) for the resale of securities by selling securityholders. It is not an earnings release, management discussion, call transcript, or other highly specific filing type. There is no dedicated category for a prospectus in the taxonomy, so this falls into the general regulatory filing fallback category.
2026-06-04 English
20-F - Aptorum Group Ltd (0001734005) (Filer)
Annual Report
2026-03-27 English
6-K Filing
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, Aptorum Group Limited, with the SEC. It specifically states that it is providing the proxy statement for the 2025 annual general meeting of shareholders, including the notice of the meeting and the proxy card. The document does not contain the full annual report or financial statements but rather materials related to the AGM, such as the proxy statement and proxy card. The document length is 3203 characters, which is relatively short and consistent with a proxy statement filing rather than a full report. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2026-02-06 English
S-4/A Filing
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Pre-Effective Amendment No. 1 to a Form S-4 Registration Statement filed with the SEC. It includes a preliminary proxy statement/prospectus related to a merger transaction involving Aptorum Group Limited and DiamiR Biosciences Corp. The text discusses the merger agreement, domestication of the company from Cayman Islands to Delaware, share issuance, stock incentive plan, director appointments, and shareholder meeting proposals. The document is a registration statement and proxy statement related to a merger and capital restructuring, not a full annual or quarterly report, earnings release, or other financial report. It is primarily a merger-related filing with proxy solicitation materials. Therefore, the most appropriate classification is Proxy Solicitation & Information Statement (PSI). The document length is substantial and contains detailed merger and proxy information, supporting high confidence in this classification.
2026-01-21 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a shelf registration statement used to register securities for sale, including Class A ordinary shares, preferred shares, warrants, units, and debt securities. The document includes detailed information about the offering, terms of securities, plan of distribution, selling shareholders, and legal matters. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full registration statement, not a brief announcement or certification, supporting high confidence in this classification.
2026-01-16 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.